



### TABLE OF CONTENTS

---

|   |                                 |            |
|---|---------------------------------|------------|
| ● | <b>Description</b>              | <b>p.1</b> |
| ● | <b>Audience</b>                 | <b>p.1</b> |
| ● | <b>Impact Factor</b>            | <b>p.2</b> |
| ● | <b>Abstracting and Indexing</b> | <b>p.2</b> |
| ● | <b>Editorial Board</b>          | <b>p.2</b> |
| ● | <b>Guide for Authors</b>        | <b>p.5</b> |



ISSN: 0024-3205

### DESCRIPTION

---

*Life Sciences* is an international journal publishing articles that emphasize the **molecular, cellular, and functional basis of therapy**. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed.

The Journal favors publication of full-length papers where modern scientific technologies are used to explain **molecular, cellular and physiological mechanisms**. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the **life sciences**. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams.

Manuscripts should present novel preclinical findings addressing questions of **biological significance to human disease**. Studies that fail to do so may be rejected without review. Quantitative conclusions must be based on truly quantitative methods. *Life Sciences* does not publish work on the actions of biological extracts of unknown chemical composition. Compounds studied must be of known chemical structure and concentration. The study must be reproducible; materials used must be available to other researchers so they can repeat the experiment. Clinical studies may be considered if they expand understanding of mechanism, but the journal does not encourage clinical trial reports.

Four common reasons for rejection include: out of scope (the manuscript does not conform to the goal of identification of mechanisms related to therapy for human disease); too preliminary (manuscript is based on a limited amount of experimental data diminishing significance); lack of novelty (manuscript is well done but does not address a significant question); unidentified structure (actions of biological extracts of unknown chemical composition).

### AUDIENCE

---

Pharmacologists, microbiologists, toxicologists, neurobiologists, immunologists.

## IMPACT FACTOR

---

2013: 2.296 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

---

BIOSIS  
Biological and Agricultural Index  
Elsevier BIOBASE  
Current Contents  
MEDLINE®  
EMBASE  
Energy Data Base  
Energy Research Abstracts  
Nutrition Abstracts  
Ophthalmic Literature  
PASCAL/CNRS  
PsycINFO Psychological Abstracts  
PsycLIT CD-ROM  
Reference Update  
Scopus  
EMBiology

## EDITORIAL BOARD

---

### *Editor-in-Chief:*

**L.E. Wold**, 603 Dorothy M. Davis Heart and Lung Research Institute, Ohio State University, 473 12th Avenue, Columbus, Columbus, OH 43210, Ohio, USA

### *Executive Editors:*

**F. Sheikh**, School of Medicine, Dept. of Medicine BSB 5042, University of California at San Diego (UCSD), 9500 Gilman Drive, Mail code: 0613C, La Jolla, 92093, California, USA

**A. ZanESCO**, Dept. of Physical Education, Inst. of Biosciences, Universidade Estadual Paulista (UNESP), Rio Claro (SP), Brazil

**C. K. Combs**, School of Medicine and Health Sciences, University of North Dakota, 504 Hamline Street Neuroscience Building, Grand Forks, ND 58203, North Dakota, USA

### *Managing Editor:*

**C. Kisthardt**, Tucson, Arizona, USA

### *Reviews Editor:*

**M. Velten**, Rheinische Friedrich-Wilhelms-University, Bonn, Germany

### *Associate Editors:*

**B.J. Biesiadecki**, Columbus, Ohio, USA

**D.J. Canney**, Philadelphia, Pennsylvania, USA

**J. Chichorro**, Curitiba - PR, Brazil

**K. De Angelis**, San Paulo, Brazil

**C. de Moraes**, Ribeirão Preto, SP, Brazil

**M. Falvo**, East Orange, New Jersey, USA

**C.M. Flores**, Titusville, New Jersey, USA

**F. Gao**, Xi'an, China

**J.D. Gardner**, New Orleans, Louisiana, USA

**O. Gualillo**, Santiago de Compostela, Spain

**D. Heymann**, Nantes cedex 3, France

**A.N.T. Kong**, Piscataway, New Jersey, USA

**J. Li**, Buffalo, New York, USA

**Y. Liu**, Columbus, Ohio, USA

**P. Moos**, Salt Lake City, Utah, USA

**H. Mukhtar**, Madison, Wisconsin, USA

**G.G. Nomikos**, Deerfield, IL, USA

**C. Samuel**, Melbourne Parkville, Victoria, Australia

**D.J. Sellers**, Robina, Queensland, Australia

**K. Singh**, Johnson City, Tennessee, USA  
**Q. Sun**, Columbus, Ohio, USA  
**L. A. Szalacha**, Columbus, Ohio, USA  
**S.J. Ward**, Philadelphia, Pennsylvania, USA  
**C.L. Willis**, Biddeford, Maine, USA  
**J. Yu**, Hong Kong, China  
**Y.-C. Zhu**, Shanghai, China

#### ***Ethics Board***

##### ***East Asia:***

**H. Anni**, Temple University, Philadelphia, Pennsylvania, USA  
**N. Emoto**  
**F. Gao**, Fourth Military Medical University, Xi'an, China  
**R. Liao**, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA  
**Q. Sun**, Ohio State University, Columbus, Ohio, USA

##### ***Europe:***

**H. Anni**, Temple University, Philadelphia, Pennsylvania, USA  
**S. Brain**, King's College London, London, England, UK

##### ***India:***

**H. Anni**, Temple University, Philadelphia, Pennsylvania, USA  
**P.K. Mukherjee**, Jadavpur University, Kolkata, India

##### ***Middle East & Iran:***

**M. Abdollahi**, Tehran University of Medical Sciences, Tehran, Iran  
**H. Anni**, Temple University, Philadelphia, Pennsylvania, USA

##### ***North America:***

**H. Anni**, Temple University, Philadelphia, Pennsylvania, USA  
**S. Teich**, Nationwide Children's Hospital, Columbus, Ohio, USA

##### ***South America:***

**H. Anni**, Temple University, Philadelphia, Pennsylvania, USA  
**C.A.C Pedra**

##### ***Editorial Advisory Board:***

**T. Abbruscato**, Amarillo, Texas, USA  
**N. Ahmad**, Madison, Wisconsin, USA  
**E. Antunes**, Campinas (SP), Brazil  
**J.C. Chatham**, Birmingham, Alabama, USA  
**A.J. Davidoff**, Biddeford, Maine, USA  
**E.A. Decker**, Amherst, Massachusetts, USA  
**F.J. Ehlert**, Irvine, California, USA  
**S.J. Enna**, Kansas City, Kansas, USA  
**G. Ertl**, Würzburg, Germany  
**A. Gugliucci**, Mare Island, Vallejo, California, USA  
**K. Gulya**, Szeged, Hungary  
**T. Haga**, Toshima-Ku, Japan  
**J. Heller Brown**, La Jolla, California, USA  
**D.G. Johnson**, Tucson, Arizona, USA  
**R.A. Kloner**, Los Angeles, California, USA  
**B. Levant**, Kansas City, Kansas, USA  
**R. Liao**, Boston, Massachusetts, USA  
**U. Mende**, Providence, Rhode Island, USA  
**T.W. Moody**, Bethesda, Maryland, USA  
**T.R. Nurkiewicz**, Morgantown, West Virginia, USA  
**K. Ohashi**, Oita, Japan  
**G. Pei**, Shanghai, China  
**R. Quirion**, Montreal, Quebec, Canada  
**R. Quock**, Pullman, Washington, USA  
**V. Ralevic**, Nottingham, England, UK  
**A.V. Schally**, Miami, Florida, USA  
**D. Stamer**, Durham, North Carolina, USA  
**Y.-J. Surh**, Seoul, South Korea  
**T. Suzuki**, Shinagawa-Ku, Japan  
**G. Tsujimoto**, Kyoto, Japan

**H. Ueda**, Nagasaki, Japan  
**D.P. Westfall**, Reno, Nevada, USA  
**S. Yamada**, Shizuoka-Shi, Japan  
**Y. Yoneda**, Kanazawa, Japan

***Editor Emeritus:***

**Frank Porreca**

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

*Life Sciences* is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. All articles are rigorously reviewed. The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research.

The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of focused reviews containing high-quality artwork and mechanistic diagrams.

### IMPORTANT INFORMATION

- Submission of a paper will be held to imply that the manuscript contains original unpublished work and is not being submitted for publication elsewhere.
- Manuscripts should present novel findings addressing significant biological questions. Studies that fail to do so may be rejected without review.
- Quantitative conclusions must be based on truly quantitative methods.
- *Life Sciences* does not publish work on the actions of biological extracts of unknown chemical composition. Compounds studied must be of known chemical structure and concentration.
- The study must be reproducible; materials used must be available to other researchers so they can repeat the experiment.

For more details on how to write a world class paper, please visit our [Pharmacology Author Resources](#) page.

**Please include word count and figure/table count on the cover page of your manuscript.**

**Authors are encouraged to submit video material or animation sequences** to support and enhance your scientific research. For more information please see the paragraph on video data below.

### *Types of article*

- Original research articles
- Reviews

### BEFORE YOU BEGIN

#### *Ethics in publishing*

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

#### *Human and animal rights*

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments [http://ec.europa.eu/environment/chemicals/lab\\_animals/legislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm); Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

#### *Conflict of Interest Policy*

The Journal requires full disclosure of all potential conflicts of interest. At the end of the manuscript text, under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence

(bias) their work. If there are no conflicts of interest, the authors should state: "The authors declare that there are no conflicts of interest." See also <http://www.elsevier.com/conflictsofinterest>. A signed [Conflict of Interests Policy Form](#) is required upon submission. The corresponding author is responsible for completing the form, and signing it on behalf of all authors.

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

### *Authorship*

All authors listed on your paper must have made significant contributions to the study. To ensure clarity, you are required upon submission to enter the specific details of each author's contribution, which must substantiate the inclusion of each person on the manuscript. This information is required to be filled in on the [Conflict of Interests Policy and Author Statement Form](#).

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Copyright**

This journal offers authors a choice in publishing their research: Open access and Subscription.

### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

### **Retained author rights**

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.  
Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY):** lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The **open access** publication fee for this journal is **\$3000**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Submission**

Submission to this journal proceeds totally online. Use the following guidelines to prepare your article. Via the homepage of this journal (<http://www.elsevier.com/journals>) you will be guided stepwise through the creation and uploading of the various files. The system automatically converts source files to a single Adobe Acrobat PDF version of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail and via the author's page in EES, removing the need for a hard-copy paper trail.

Specific queries can be directed to [lifesci@elsevier.com](mailto:lifesci@elsevier.com).

### **Referees**

To expedite the review process, authors must submit names of 4 - 6 individuals who are qualified to review their work. Include the email address of each potential referee, as much contact information as possible, and why you feel this person is competent to review your work. You should not have collaborated with the suggested reviewers at any time in the past five years. In our effort to enhance global perspective and communication of science, these individuals should be associated with institutions from as many different regions as possible (Europe, North America, Asia, etc.). Exception: Symposium submissions which have been previously reviewed and approved by their Organizing Committee.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### **Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.



## Language

Please write your text in good English (American or British usage is accepted, but not a mixture of these). For language assistance, please see Language Services, above. Use decimal points (not decimal commas); use a space for thousands (10 000 and above).

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## Organization of the manuscript

Beginning with the first page, present your manuscript in the order below:

1. Title: First letter capitalized, subsequent letters in lower case. Maximum length 150 characters including spaces. Avoid abbreviations.

2a. Names of all authors.

2b. Affiliations of all authors. If necessary, use superscripted lowercase letters after the author's name to distinguish affiliations.

3. Author to whom proofs and correspondence should be sent, including name, mailing address, telephone and fax numbers, and e-mail address.

4. A structured abstract has to be submitted for full length articles (not for reviews) of no more than 250 words. The following headings must be used:

Aims:

Main methods:

Key findings:

Significance:

5. Three or more key words for indexing purposes. In addition to key words from the title, please suggest other terms that help define the study. We encourage authors to test the relevance of their key words by using them for a database search and comparing the results with the topic of their own paper.

**Word limits:** In **full papers**, individual sections should be no longer than Abstract 250 words, Introduction 500 words, Discussion 1500 words, Conclusion 150 words. Materials and Methods and Results sections should be concise but there is no formal word limit.

**Headings:** Papers must include the major headings Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgments, and References. Include subheadings as appropriate. Review articles must contain Abstract and Introduction, with subsequent headings and subheadings as appropriate.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section.

The Graphical Abstract is optional for research articles, but mandatory for reviews. GAs should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Graphical abstracts should be submitted as a separate file in the online submission system. Refer to the following website for more information <http://www.elsevier.com/graphicalabstracts>.

### **Chemical compounds**

You can enrich your article by providing a list of chemical compounds studied in the article. The list of compounds will be used to extract relevant information from the NCBI PubChem Compound database and display it next to the online version of the article on ScienceDirect. You can include up to 10 names of chemical compounds in the article. For each compound, please provide the PubChem CID of the most relevant record as in the following example: Glutamic acid (PubChem CID:611). The PubChem CIDs can be found via <http://www.ncbi.nlm.nih.gov/pccompound>. Please position the list of compounds immediately below the 'Keywords' section. It is strongly recommended to follow the exact text formatting as in the example below:

Chemical compounds studied in this article

Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865)

More information is available at: <http://www.elsevier.com/PubChem>.

### **Abbreviations**

Abbreviations must be explained the first time they are used, both in the Abstract and again in the main text.

Abbreviations used as names of cell lines do not need to be explained, but the species and tissue of origin should be made clear in text the first time the cell line is mentioned. Examples: "the human colonic adenocarcinoma cell line Caco-2" or "the porcine renal endothelial cell line LLC-PK1".

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Please note that funding information must appear under the Acknowledgments heading.

### **Database linking**

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### **Artwork**

*Electronic artwork*

*General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

### Formats

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

### Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

## References

### Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

- Single author (Smith 2003)
- Two authors (Smith and Thompson 2003)
- Three or more authors (Smith et al. 2003) (N.B.: note period after et al.)
- Multiple references (Smith et al. 2003; Jones et al. 2003) (N.B.: note semicolon)
- Same author(s), same year (Smith and Thompson 2000a,b,c)
- Same author(s), different years (Smith et al. 1999, 2001)

### Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

### Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be

applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

#### *Reference style*

*Text:* All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
2. *Two authors:* both authors' names and the year of publication;
3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ....'

*List:* References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

*Examples:*

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59.

Reference to a book:

Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

#### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

#### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

#### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

## Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

### Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

## AFTER ACCEPTANCE

### Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### Offprints

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

## AUTHOR INQUIRIES

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

